Payment overview · 2025
General Payments
$277.69
13 reported records · 6 companies
Healthcare provider profile · identity verified
Cara M. Ricotta, DO
Allopathic & Osteopathic Physicians|Family Medicine · STATE COLLEGE, PA · NPI 1275781569
Verified facts
What the public records show
CMS Open Payments records show Cara M. Ricotta, DO received $277.69 in general payments during 2025 across 13 reported records.
ABBVIE INC. accounted for 34.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.32 | 34.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.10 | 22.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.33 | 19.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.98 | 8.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.14 | 7.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.82 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.69 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.32 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.95 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $63.10 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $63.10 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $63.10 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 196 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 170 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
170 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 856 | 294 |
| Levothyroxine Sodium | Levothyroxine Sodium | 726 | 203 |
| Lisinopril | Lisinopril | 494 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 437 | 165 |
| Losartan Potassium | Losartan Potassium | 436 | 152 |
| Omeprazole | Omeprazole | 347 | 129 |
| Gabapentin | Gabapentin | 341 | 91 |
| Metformin Hcl | Metformin Hcl | 323 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 100 |
| Famotidine | Famotidine | 305 | 104 |
| Sertraline Hcl | Sertraline Hcl | 301 | 95 |
| Furosemide | Furosemide | 279 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 97 |
| Lorazepam | Lorazepam | 228 | 52 |
| Tramadol Hcl | Tramadol Hcl | 213 | 36 |
| Potassium Chloride | Potassium Chloride | 210 | 63 |
| Eliquis | Apixaban | 196 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 178 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 46 |
| Ozempic | Semaglutide | 170 | 35 |
| Simvastatin | Simvastatin | 170 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 63 |
| Allopurinol | Allopurinol | 165 | 40 |
| Trazodone Hcl | Trazodone Hcl | 165 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 55 |
| Metformin Hcl Er | Metformin Hcl | 151 | 47 |
| Meloxicam | Meloxicam | 118 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 115 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 114 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 36 |
| Montelukast Sodium | Montelukast Sodium | 111 | 41 |
| Jardiance | Empagliflozin | 108 | 34 |
| Alprazolam | Alprazolam | 104 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 43 |
| Pregabalin | Pregabalin | 101 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 29 |
| Alendronate Sodium | Alendronate Sodium | 90 | 35 |
| Buspirone Hcl | Buspirone Hcl | 90 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 23 |
| Carvedilol | Carvedilol | 87 | 28 |
| Atenolol | Atenolol | 83 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 83 | 67 |
| Spironolactone | Spironolactone | 82 | 30 |
| Synthroid | Levothyroxine Sodium | 82 | 27 |
| Xarelto | Rivaroxaban | 82 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 24 |
| Celecoxib | Celecoxib | 70 | 23 |
| Prednisone | Prednisone | 70 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 21 |
| Ezetimibe | Ezetimibe | 65 | 24 |
| Nystatin | Nystatin | 65 | 33 |
| Warfarin Sodium | Warfarin Sodium | 65 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 59 | 15 |
| Glipizide | Glipizide | 59 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 13 |
| Methylprednisolone | Methylprednisolone | 57 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 48 |
| Glimepiride | Glimepiride | 51 | 16 |
| Klor-Con M20 | Potassium Chloride | 49 | 21 |
| Methocarbamol | Methocarbamol | 47 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 14 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 16 |
| Linzess | Linaclotide | 38 | 20 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 14 |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 34 | 21 |
| Valacyclovir | Valacyclovir Hcl | 34 | 21 |
| Azelastine Hcl | Azelastine Hcl | 33 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Finasteride | Finasteride | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 14 |
| Meclizine Hcl | Meclizine Hcl | 30 | 16 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 18 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 15 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Naproxen | Naproxen | 24 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Klayesta | Nystatin | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nayzilam | Midazolam | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.69 · 13 records | ABBVIE INC. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, KRYSTEXXA, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error